Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06088303 · ClinicalTrials.gov registry record · NA

Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication

A NA study of Stress Disorders, Post-Traumatic, sponsored by Boston University.

Recruiting
Registry status
NA
Development phase
54
Enrollment target
1
Study location

NCT06088303 is a NA study of Stress Disorders, Post-Traumatic that is actively recruiting participants, run by Boston University. The registered enrollment target is 54 participants, below the 155-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06088303, a NA study of Stress Disorders, Post-Traumatic, is actively recruiting participants, sponsored by Boston University.

RECRUITING
Registry status
NA
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to learn whether existing treatments for posttraumatic stress disorder (PTSD) can be improved. Two treatments for PTSD, cognitive processing therapy (CPT) and prolonged exposure (PE) will be studied. CPT and PE are effective treatments that are widely available, but interventions are needed to improve patient outcomes in these treatments. The investigators have developed an Adjunctive Writing intervention for Amplifying Response and Engagement (AWARE), which was designed using health communication strategies to enhance CPT and PE by improving communication between patients and therapists about patients' experiences in treatment. This research will investigate whether adding AWARE to CPT and PE will lead to better treatment outcomes compared to CPT and PE provided as usual without AWARE. AWARE includes a brief writing task asking patients about their experiences in treatment, as well as guided therapist responses to improve patient-therapist communication about patients' experiences in treatment. In the first phase of the study (case series phase), CPT or PE with AWARE will be provided to four adults with PTSD to pilot test adding AWARE to CPT and PE, seek patient and provider feedback, and refine AWARE. The first four participants who enroll will be part of the case series and will receive CPT or PE with AWARE. Then, in the second phase of the study, the randomized controlled trial (RCT) phase, the investigators will enroll 50 more adults with PTSD who will be randomly assigned (like flipping a coin) to receive CPT/PE as usual or CPT/PE with AWARE. It is expected that 25 participants will be randomized to CPT/PE with AWARE and 25 participants will be randomized to receive CPT/PE provided as usual. The goals of the RCT phase are to study whether AWARE is acceptable to patients, whether it is feasible to add AWARE to CPT and PE, and whether adding AWARE to CPT and PE improves patient-therapist communication and treatment outcomes

Interventions

  • BEHAVIORAL Adjunctive writing to amplify response and engagement (AWARE)
  • BEHAVIORAL Cognitive processing therapy (CPT)
  • BEHAVIORAL Prolonged exposure (PE)

Study Locations (1)

Massachusetts

  • National Center for PTSD at VA Boston Healthcare System - Boston

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2025-01-15
Est. Completion 2028-12-31
Phase NA

Sponsor

Boston University

185 total trials

What the Registry Record Tells You About NCT06088303

The ClinicalTrials.gov registry entry for NCT06088303 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (65% lower). The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 3 interventions - of which Adjunctive writing to amplify response and engagement (AWARE) is the first listed.

NCT06088303 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06088303 about?

NCT06088303 is a clinical study titled "Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication". The purpose of this clinical trial is to learn whether existing treatments for posttraumatic stress disorder (PTSD) can be improved. Two treatments for PTSD, cognitive processing therapy (CPT) and prolonged exposure (PE) will be studied. CPT and PE are effective treatments that are widely available,...

What is the current status of trial NCT06088303?

This trial is currently recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2025-01-15. Estimated completion is 2028-12-31.

What conditions does trial NCT06088303 study?

This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic.

What interventions are being tested in trial NCT06088303?

The interventions under investigation include: Adjunctive writing to amplify response and engagement (AWARE) (BEHAVIORAL), Cognitive processing therapy (CPT) (BEHAVIORAL), Prolonged exposure (PE) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06088303?

This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06088303 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stress Disorders, Post-Traumatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.